Join        Login             Stock Quote

Chembio Diagnostics (CEMI) Jumps After FDA Clears New Rapid HIV Test

 December 21, 2012 10:15 AM

(By Balachander) Chembio Diagnostics Inc. (NASDAQ: CEMI) shares are spiking in early Friday trading after the U.S. health regulators approved its new test to detect HIV-1/2 antibodies in either oral fluid or blood samples.

The U.S. Food and Drug Administration (FDA) cleared Chembio's Dual Path Platform (DPP) HIV 1/2 assay, allowing the company to market a point-of-care (POC) oral fluid rapid diagnostic test.

Chembio said it expects to launch DPP HIV 1/2 in the U.S. during the second half of 2013.

The company believes the new rapid diagnostic test has superior performance compared with the only other oral fluid HIV rapid test on the market.

The diagnostic assay, the company said, uses the patented DPP technology for the rapid detection of HIV 1 and HIV 2 antibodies in all blood matrices and oral fluid.

The Chembio DPP HIV 1/2 Assay is a single-use immuno-chromatographic, rapid test for the detection of antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV 1/2) in oral fluid, finger-stick whole blood, venous whole blood, serum, or plasma samples.

According to the company, DPP enables samples to bind directly with target analytes before detection reagents are introduced to visualize the test results, and can improve accuracy compared with the current lateral flow HIV test technologies

The stock, which has been trading in the 52-week range of $2.96 to $5.78, traded 18.89 percent higher at $5.47 on Friday.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

article imageIs The Slump In US Manufacturing Easing?

Yesterday’s November survey data from the Philadelphia Fed hints at the possibility that a stronger trend read on...

Popular Articles

Daily Sector Scan
Partner Center

Related Articles:

Recent Articles by Balachander
More Articles on: Medical

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.